Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:16:12.912Z.
Calculation as of: 2026-10-06T16:16:12.912Z.
Quote observation: 2026-10-06T16:13:48.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1c5d1a4dd2ed90e95308857a7b7df8ea0860f9bef9a655807fa9e02aea5f37e0
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cellectar Biosciences, Inc. (CLRB) | $12.86M | N/A | N/A | N/A | N/A |
| Lantern Pharma Inc. (LTRN)vs › | $13.01M | N/A | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $12.88M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.60M | N/A | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.56M | N/A | N/A | N/A | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.56M | N/A | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $12.37M | N/A | 245.86 | 105.92 | 78.24 |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.89M | N/A | N/A | N/A | N/A |
| IN8bio, Inc. (INAB)vs › | $13.89M | N/A | N/A | N/A | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.81M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.61
Forward EPS (Est.)
$-2.43
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
